Ona Therapeutics, SL

Ona Therapeutics is a biotechnology company focused on developing innovative antibody drug conjugates for advanced cancer treatments, particularly for patients with limited therapeutic options. Founded in 2019, Ona Therapeutics, SL is based in Barcelona, Spain, and specializes in developing therapeutics for oncology. The company has raised EUR 30. 00 mn in its Series A funding round on June 16, 2020, from notable investors including Alta Life Sciences, Asabys Partners, Bpifrance Investissement, Fund+, and Ysios Capital Partners.

The founders, Salvador Benitah and Valerie Vanhooren, have significant experience in the industry and lead the company's strategic initiatives. Ona Therapeutics specializes in the development of first-in-class antibody drug conjugates (ADCs) aimed at addressing the unmet medical needs of patients with advanced cancers, particularly those who have become refractory to existing treatments. The company’s pipeline includes innovative therapies, such as an undisclosed ADC targeting refractory breast cancer patients and another ADC for prevalent solid tumors. Additionally, Ona is developing a monoclonal antibody that targets CD36, a key metabolic regulator implicated in cancer progression.

Their therapeutic solutions cater primarily to oncology practices and clinical institutions, focusing on North America and Europe. Ona Therapeutics generates revenue primarily through strategic partnerships and collaborations with academic institutions and clinical research organizations. These partnerships involve co-development agreements, where partners contribute funding for clinical trials in exchange for future royalties or profit-sharing from successful product launches. Revenue is also supplemented by grants and public funding that supports ongoing research and development efforts while maintaining robust operations.

Specific pricing structures for products are determined during the commercialization phase. Ona Therapeutics plans to leverage its recent funding of EUR 30. 00 mn from the Series A round to advance its product pipeline, including upcoming ADCs designed for specific cancer indications. The company is strategically targeting expansion into North America and Europe by 2025, aiming to establish more partnerships and enhance its clinical trial capabilities.

The funding will support the development of their innovative therapies and facilitate entry into new markets.